Whether antiandrogen therapy with radiation therapy will further improve cancer control and prolong overall survival is unknown. In a double-blind, placebo-controlled trial conducted from 1998 ...

Adding antiandrogen therapy to radiotherapy as a salvage treatment for men with biochemical recurrence following prostatectomy improves outcomes. It extends overall survival (OS) and reduces the ...

Objective: To present management options for gynaecomastia and mastodynia associated with nonsteroidal antiandrogen therapy, supported by relevant data and case studies. Background: Gynaecomastia ...

According to a two-by-two factorial design, patients were randomly assigned to receive one of the following treatments: pure antiandrogen plus placebo (A+P group, 60 patients); luteinizing ...

Patients who began receiving luteinizing hormone–releasing hormone agonist (LHRHa) therapy with or without an antiandrogen agent a maximum of 6 months before enrollment and who met all the ...

Women taking the synthetic progestogen cyproterone acetate were at increased risk for brain tumors, a French study found. The analysis of data on over 250,000 girls and women who filled a ...

ARN-509 is a second-generation antiandrogen that emerged from a structure/activity relationship–guided medicinal chemistry program to design more potent antiandrogens with no significant agonistic ...

Prostate cancer patients that don't respond to usual hormonal treatments are given enzalutamide, which is an androgen receptor inhibitor, also known as an antiandrogen. These medications block ...

In a study, men who had pre-existing cardiovascular disease prior to taking abiraterone or enzalutamide for advanced prostate cancer had a 16% to 56% increased 6-month risk. Pre-existing ...

Rüdiger Meyer Shipley WU, Seiferheld W, Lukka HR, et al.: Radiation with or without antiandrogen therapy in recurrent prostate cancer. N Engl J Med 2017; 376: 417–428.